Abstract

Accumulating evidence indicates that the innate and adaptive immune systems make a crucial contribution to the antitumour effects of conventional chemotherapy-based and radiotherapy-based cancer treatments. Moreover, the molecular and cellular bases of the immunogenicity of cell death that is induced by cytotoxic agents are being progressively unravelled, challenging the guidelines that currently govern the development of anticancer drugs. Here, we review the immunological aspects of conventional cancer treatments and propose that future successes in the fight against cancer will rely on the development and clinical application of combined chemo- and immunotherapies.

Author affiliations

1. INSERM, U805, Institut Gustave Roussy, 39 Rue Camille Desmoulins, F-94805 Villejuif, Paris, France.
2. CIC BT507, Institut Gustave Roussy, 39 Rue Camille Desmoulins, F-94805 Villejuif, Paris, France.
3. Faculté de Médecine Paris Sud-Université Paris XI, 63 Rue Gabriel Péri, 94276 Le Kremlin Bic^tre Cedex, France.
4. Centre Georges-François Leclerc, 1 Rue du Professeur Marion, 21000 Dijon, France.
5. INSERM, U848, Institut Gustave Roussy, Pavillon de Recherche 1, 39 Rue Camille Desmoulins, F-94805 Villejuif, Paris, France.

Correspondence to: Laurence Zitvogel^1,2,3 Email: zitvogel@igr.fr

Correspondence to: Guido Kroemer^3,5 Email: kroemer@igr.fr

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.